Clinical Trial Search

Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale

Primary: The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient…

Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants

Primary: Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated…

Primary: Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline — -5.4; -15.2 percent change in mean growth rate — p=0.57

Primary: Human Papillomavirus Genotypes — 6; 9 participants

Primary: Proportion of Participants With a Complete Response — 0; 0 proportion of participants

Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 33.3; 66.7; 75.0; 62.5 percentage of participants

Primary: Disease-free Survival at 2 Years — 111 Participants

Primary: Radiographic Responses, Determined by RECIST 1.1 Criteria — 5; 4; 3 Participants

Primary: Presence of Reflux in Patients With Polyposis — 15 participants

Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants

Primary: Physician Global Assessment of Disease Activity — 21; 14; 12; 43 mm

Primary: Rate of Retinal Attachment — 50; 42 Participants

Primary: Occurrences of Pneumonia — 4; 3 Participants

Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants

Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change

Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants

Primary: Change in the Maximum Size of the Genital Wart Lesion Over the Trial Period (as Measured in mm) — 8; 6; 11; 7 Participants

Primary: To Explore if Ribavirin Therapy for 2 Weeks Decreases Tumor Expression — 4; 2; 3 Participants

Primary: The Primary Endpoint of This Study is Persistence and Recurrence of Anal Warts as Compared Between the Experimental and Control Groups. — 1; 1 participants

Primary: Number of Participants With Recurrence of Dysplasia — 5; 8 Participants

Primary: Control Status of Patients With Rhinosinusitis — 19.5; 36.8; 43.7 percentage of participants

Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants

Primary: Primary Endpoint: Number of Subjects That Develop New, Active Bleeding — 0 Participants

Primary: Time-Weighted Average Change in Nasal Respiratory Syncytial Virus (RSV ) Viral Load From Baseline (Day 1) to Day 9 — -1.26; -0.91 log10 copies/mL — p=0.040

Primary: Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set — -0.73; -0.90 log10 copies/mL — p=0.72

Primary: Performance — 0 Participants

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 15; 9; 11; 4 Participants